Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen A Beers

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Blood|November 2, 2013
Neutrophils: "neu players" in antibody therapy?Stephen A Beers, Martin J Glennie
Cancers|October 13, 2021
Remodeling the Tumor Myeloid Landscape to Enhance Antitumor Antibody ImmunotherapiesKhiyam Hussain, Mark S Cragg, Stephen A Beers
Blood|December 26, 2009
Complement: help or hindrance?Stephen A Beers, Mark S Cragg, Martin J Glennie
Pharmacological Research|July 19, 2015
Antibody modulation: Limiting the efficacy of therapeutic antibodiesAndrew T Vaughan, Mark S Cragg, Stephen A Beers
Current Topics in Microbiology and Immunology|August 14, 2014
FcγRIIB as a key determinant of agonistic antibody efficacyAnn L White, Stephen A Beers, Mark S Cragg
Cancer Letters|May 6, 2019
PD-1/PD-L1 blockade in paediatric cancers: What does the future hold?Julia Moreno-Vicente, Stephen A Beers, Juliet C Gray
Blood|January 15, 2016
Influence of immunoglobulin isotype on therapeutic antibody functionStephen A Beers, Martin J Glennie, Ann L White
Glycobiology|May 26, 2018
Through the barricades: overcoming the barriers to effective antibody-based cancer therapeuticsMartin Dalziel, Stephen A Beers, Mark S Cragg, et al.
Breast Cancer Research : BCR|September 12, 2023
The role of three-dimensional in vitro models in modelling the inflammatory microenvironment associated with obesity in breast cancerRhianna Rachael Romany Blyth, Charles N Birts, Stephen A Beers
Immunological Reviews|October 27, 2015
FcγR requirements leading to successful immunotherapyLekh N Dahal, Ali Roghanian, Stephen A Beers, et al.
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Blood|November 2, 2013
Neutrophils: "neu players" in antibody therapy?Stephen A Beers, Martin J Glennie
Cancers|October 13, 2021
Remodeling the Tumor Myeloid Landscape to Enhance Antitumor Antibody ImmunotherapiesKhiyam Hussain, Mark S Cragg, Stephen A Beers
Blood|December 26, 2009
Complement: help or hindrance?Stephen A Beers, Mark S Cragg, Martin J Glennie
Pharmacological Research|July 19, 2015
Antibody modulation: Limiting the efficacy of therapeutic antibodiesAndrew T Vaughan, Mark S Cragg, Stephen A Beers
Current Topics in Microbiology and Immunology|August 14, 2014
FcγRIIB as a key determinant of agonistic antibody efficacyAnn L White, Stephen A Beers, Mark S Cragg
Cancer Letters|May 6, 2019
PD-1/PD-L1 blockade in paediatric cancers: What does the future hold?Julia Moreno-Vicente, Stephen A Beers, Juliet C Gray
Blood|January 15, 2016
Influence of immunoglobulin isotype on therapeutic antibody functionStephen A Beers, Martin J Glennie, Ann L White
Glycobiology|May 26, 2018
Through the barricades: overcoming the barriers to effective antibody-based cancer therapeuticsMartin Dalziel, Stephen A Beers, Mark S Cragg, et al.
Breast Cancer Research : BCR|September 12, 2023
The role of three-dimensional in vitro models in modelling the inflammatory microenvironment associated with obesity in breast cancerRhianna Rachael Romany Blyth, Charles N Birts, Stephen A Beers
Immunological Reviews|October 27, 2015
FcγR requirements leading to successful immunotherapyLekh N Dahal, Ali Roghanian, Stephen A Beers, et al.
Pageof 8